Novartis Pharma AG and Novartis Pharmaceuticals Corporation /
AVROBIO
Novartis completes purchase of AVROBIO gene therapy program
- Price
- $87.5m
- Stage
- Closed
What happened
Novartis Pharma AG and Novartis Pharmaceuticals Corporation completed their purchase of AVROBIO, Inc.’s cystinosis gene therapy program and related assets on June 9, 2023.
The transaction included $87.5 million in cash paid at closing. AVROBIO is a clinical-stage gene therapy company.
The source
Everything on this page comes from the source below.
Novartis completes purchase of AVROBIO gene therapy program
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly